🔬 Alltrna Slims Down Ahead of Its tRNA Medicines’ First Human Trial Flagship Pioneering-backed Alltrna is repositioning as it nears its first clinical milestone—cutting 8 jobs (12%) to refine operations around its upcoming tRNA-based therapy, engineered to tackle Stop Codon Diseases like PKU and organic acidemias. Why this matters: Alltrna's cutting-edge platform uses AI/ML to design tRNAs that ‘read through’ premature stop codons, enabling protein restoration in a broad class of genetic diseases (~10% of rare disorders) Despite the recent layoff, leadership says the clinical strategy is intact, with full focus on transitioning from preclinical to first-in-human studies The move echoes broader biotech realities: carefully calibrating scale and runway before clinic—with >$109M raised to date, including Flagship’s initial $50M commitment Alltrna represents a pioneering approach—tRNA medicines could eventually treat thousands of diseases caused by the same genetic logic. As the platform enters the clinic, this workforce adjustment signals readiness and precision. 🧬 #Alltrna #FlagshipPioneering #tRNAMedicine #RareDisease #Preclinical #BiotechRestructuring #StopCodonDisease

⚙️ BioNTech Cuts 63 U.S. Jobs, Shutters Cell Therapy Plant Amid Oncology Pivot BioNTech is restructuring hard in the U.S.: it’s winding down its Gaithersburg, Maryland cell therapy facility, laying off 63 staff, and halting manufacturing after discontinuing its CLDN6-targeted CAR‑T candidate BNT211 in testicular cancer. The site is expected to shut down by year-end. This move is part of a broader global shift: BioNTech will reduce up to 1,350 jobs by 2027 across Europe and North America, while adding 800–1,200 new roles—especially at its Mainz R&D hub and the newly acquired CureVac facility. The firm is doubling down on its oncology pipeline, including ongoing development of BNT211 in other solid tumors, submission plans for ADC candidate BNT323, and a ￥1 billion expansion in the U.K. This strategic "recalibration" refocuses resources toward late-stage cancer therapeutics and mRNA innovation, while retreating from earlier cell therapy operations in the U.S. #BioNTech #Layoffs #OncologyStrategy #CellTherapy #CAR-T #mRNA #CancerResearch #BiotechRestructuring